Eton Pharmaceuticals Inc Quick Ratio (ETON) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Eton Pharmaceuticals Inc   (NASDAQ: ETON)

Eton Pharmaceuticals Inc 's Quick Ratio

ETON's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Eton Pharmaceuticals Inc 's Cash & cash equivalent grew by 107.22 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Eton Pharmaceuticals Inc 's Quick Ratio to 1.03, Quick Ratio remained below Eton Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 385 other companies have achieved higher Quick Ratio than Eton Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 2408 to 2467.

Explain Quick Ratio?
How much Cash & cash equivalents ETON´s has?
What are ETON´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ETON/financial-strength
https://api.csimarket.com/api/v1/companies/ETON/fundamentals
https://api.csimarket.com/api/v1/companies/ETON/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ETON Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 22.43 %
Y / Y Cash & cash equivalent Change 49.86 %
Quick Ratio MRQ 1.03
ETON's Total Ranking # 2467
Seq. Current Liabilities Change 19.88 %
Seq. Cash & cash equivalent Change 107.22 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 386
Healthcare Sector # 719
Overall Market # 2467


Quick Ratio Statistics
High Average Low
16.59 4.32 0.45
(Dec 31 2018)   (Mar 31 2026)




Financial Statements
Eton Pharmaceuticals Inc 's Current Liabilities $ 54 Millions Visit ETON's Balance sheet
Eton Pharmaceuticals Inc 's Cash & cash equivalent $ 56 Millions Visit ETON's Balance sheet
Source of ETON's Sales Visit ETON's Sales by Geography


Cumulative Eton Pharmaceuticals Inc 's Quick Ratio

ETON's Quick Ratio for the trailling 12 Months

ETON Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 42.02 %
Y / Y Cash & cash equivalent TTM Growth 35.02 %
Quick Ratio TTM 0.7
Total Ranking TTM # 4101
Seq. Current Liabilities TTM Growth 5.76 %
Seq. Cash & cash equivalent TTM Growth 16.89 %


On the trailing twelve months basis ETON Cash & cash equivalent soared by 49.86 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Eton Pharmaceuticals Inc 's Quick Ratio to 0.7, Quick Ratio remained below ETON average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Eton Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2970 to 4101.

Explain Quick Ratio?
How much Cash & cash equivalents ETON´s has?
What are ETON´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 907
Within the Market # 4101


trailing twelve months Quick Ratio Statistics
High Average Low
8.48 3.31 0.64
(Sep 30 2019)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Annexon Inc   2.72 $ 102.389  Millions$ 37.660  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions
Dermata Therapeutics Inc   2.40 $ 4.822  Millions$ 2.012  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Puma Biotechnology Inc   2.09 $ 108.575  Millions$ 51.971  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Biomea Fusion Inc   2.07 $ 26.403  Millions$ 12.771  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions
Lite Strategy Inc   1.92 $ 4.281  Millions$ 2.234  Millions
Mineralys Therapeutics Inc   1.91 $ 101.273  Millions$ 53.075  Millions
Amarin Corp Plcuk  1.85 $ 323.379  Millions$ 175.136  Millions
Mustang Bio inc   1.80 $ 14.276  Millions$ 7.947  Millions

Date modified: 2026-11-06T13:02:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.